At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,798 enrolled
Drug / intervention
Tumor Genetic Sequencingother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions
In Brief
A clinical study evaluating Tumor Genetic Sequencing for Neoplasm. Completed, enrolled 2,798 participants across 1 site.
Detailed Summary
The primary objective of this specimen correlative study is two-fold: to provide a mechanism for the association of known molecular alterations with clinical outcomes, and to provide rapid genetic profiling of alterations with known clinical utility using tumor and germline specimens to support treatment decisions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasm
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2011
First PostedOct 2011
Primary CompletionJun 2018
TodayJul 2026
First PostedOct 21, 2011
Enrollment StartSep 1, 2011
Primary CompletionJun 6, 2018
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 14.7 years ago
Interventions
Tumor Genetic Sequencingother
This study will look at genetic material from a sample of the subjects tumor, look at certain changes in the genetic material, and see if these changes are related to the subjects cancer.